Maryland v. King: Three Concerns about Policing and Genetic Information
By Elizabeth E. Joh,
Genomics Law Report
| 09. 19. 2013
With its decision in
Maryland v. King [pdf], the Supreme Court finally stepped into the debate about the use of DNA databases in the criminal justice system. The United States now has the largest DNA database in the world, with
10.4 million offender profiles and 1.5 million arrestee profiles as of June 2013. In
King, the Court was called upon to decide whether the Fourth Amendment prohibits the collection of DNA samples from arrestees without a warrant or probable cause, the traditional requirements of searches and seizures.
The majority opinion, written by Justice Kennedy, held that the collection of a DNA sample from an arrestee in these circumstances constituted a reasonable Fourth Amendment search, given the outcome of a balancing of interests between the government and the individual. In a sharply written dissent, Justice Scalia criticized the majority’s approval of searches that were conducted specifically for law enforcement purposes yet did not conform to traditional Fourth Amendment requirements.
While
King affirms that DNA databanking in the criminal justice system is here to stay, the majority opinion, when considered with...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...